JP2005506370A5 - - Google Patents

Download PDF

Info

Publication number
JP2005506370A5
JP2005506370A5 JP2003537639A JP2003537639A JP2005506370A5 JP 2005506370 A5 JP2005506370 A5 JP 2005506370A5 JP 2003537639 A JP2003537639 A JP 2003537639A JP 2003537639 A JP2003537639 A JP 2003537639A JP 2005506370 A5 JP2005506370 A5 JP 2005506370A5
Authority
JP
Japan
Prior art keywords
libido
acid
use according
flibanserin
loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003537639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506370A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/011103 external-priority patent/WO2003035072A1/en
Publication of JP2005506370A publication Critical patent/JP2005506370A/ja
Publication of JP2005506370A5 publication Critical patent/JP2005506370A5/ja
Pending legal-status Critical Current

Links

JP2003537639A 2001-10-20 2002-10-04 性的障害の治療におけるフリバンセリンの使用 Pending JP2005506370A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01125020 2001-10-20
PCT/EP2002/011103 WO2003035072A1 (en) 2001-10-20 2002-10-04 Use of flibanserin in the treatment of sexual disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007000124A Division JP2007131631A (ja) 2001-10-20 2007-01-04 性的障害の治療におけるフリバンセリンの使用

Publications (2)

Publication Number Publication Date
JP2005506370A JP2005506370A (ja) 2005-03-03
JP2005506370A5 true JP2005506370A5 (enExample) 2006-02-16

Family

ID=8179028

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003537639A Pending JP2005506370A (ja) 2001-10-20 2002-10-04 性的障害の治療におけるフリバンセリンの使用
JP2007000124A Withdrawn JP2007131631A (ja) 2001-10-20 2007-01-04 性的障害の治療におけるフリバンセリンの使用
JP2012000343A Pending JP2012067134A (ja) 2001-10-20 2012-01-05 性的障害の治療におけるフリバンセリンの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2007000124A Withdrawn JP2007131631A (ja) 2001-10-20 2007-01-04 性的障害の治療におけるフリバンセリンの使用
JP2012000343A Pending JP2012067134A (ja) 2001-10-20 2012-01-05 性的障害の治療におけるフリバンセリンの使用

Country Status (31)

Country Link
US (9) US7151103B2 (enExample)
EP (2) EP1674102A1 (enExample)
JP (3) JP2005506370A (enExample)
KR (3) KR101235102B1 (enExample)
CN (4) CN102125557A (enExample)
AR (2) AR037109A1 (enExample)
AT (1) ATE327757T1 (enExample)
AU (1) AU2002333894B2 (enExample)
BR (1) BR0213358A (enExample)
CA (1) CA2458067C (enExample)
CY (1) CY1105082T1 (enExample)
DE (1) DE60211937T2 (enExample)
DK (1) DK1446122T5 (enExample)
EA (1) EA007274B1 (enExample)
EC (1) ECSP045069A (enExample)
ES (1) ES2266632T3 (enExample)
HR (1) HRP20040352B1 (enExample)
HU (1) HUP0401023A3 (enExample)
IL (2) IL160389A0 (enExample)
ME (1) MEP42808A (enExample)
MX (1) MXPA04003666A (enExample)
MY (1) MY127290A (enExample)
NO (1) NO325556B1 (enExample)
NZ (1) NZ532079A (enExample)
PL (1) PL208744B1 (enExample)
PT (1) PT1446122E (enExample)
RS (1) RS50876B (enExample)
SI (1) SI1446122T1 (enExample)
UA (1) UA78974C2 (enExample)
WO (1) WO2003035072A1 (enExample)
ZA (1) ZA200401366B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
JP2007516949A (ja) * 2003-07-16 2007-06-28 ファイザー・インク 性機能不全の治療
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
JP4964593B2 (ja) 2003-09-25 2012-07-04 セノメド バイオサイエンシーズ,エルエルシー 神経学的病状の治療用のテトラヒドロインドロン誘導体
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
KR20070014184A (ko) * 2004-04-22 2007-01-31 베링거 인겔하임 인터내셔날 게엠베하 성기능 장애 치료용 신규 약제학적 조성물 ⅱ
CN101027061B (zh) 2004-05-11 2014-03-12 情感智能有限责任公司 药物制剂及其在治疗女性性功能障碍中的应用
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
EP1789048A1 (en) * 2004-09-03 2007-05-30 Boehringer Ingelheim International GmbH Method for the treatment of attention deficit hyperactivity disorder
EP1858515A2 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006096435A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
JP2008540356A (ja) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬物乱用の治療方法
CA2608713A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunctions due to medical conditions
JP2008540673A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤誘発性性機能不全の治療方法
US20080200498A1 (en) * 2005-07-12 2008-08-21 Angelo Ceci Pharmaceutical Composition For The Treatment Of Disorders Of Sexual Desire
CA2617546C (en) 2005-08-03 2014-07-15 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
WO2007110868A2 (en) 2006-03-28 2007-10-04 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
BRPI0712039A2 (pt) * 2006-05-09 2011-12-20 Boehringer Ingelheim Int uso de flibanserina para o tratamento de distúrbios de desejo sexual pós-menopausa
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
CA2657043A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
US20090239881A1 (en) * 2006-07-14 2009-09-24 Boehringer Ingelheim International Gmbh Combinations of Flibanserin with Caffeine, Process for Their Preparation and Use Thereof as Medicaments
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
WO2008022932A2 (en) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
EP2097389B1 (en) 2006-12-20 2011-09-14 Boehringer Ingelheim International GmbH Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity
US8304601B2 (en) * 2007-01-23 2012-11-06 Keiko Fujikawa Mouse model for eye disease
CA2682015A1 (en) * 2007-03-28 2008-10-02 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
PE20091188A1 (es) * 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
DE102011012712A1 (de) 2011-03-01 2012-09-06 Frank Lehmann-Horn Verwendung von Aldosteron-Rezeptor-Antagonisten zur Behandlung von weiblicher sexueller Dysfunktion
WO2012140642A1 (en) 2011-04-10 2012-10-18 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
US9517254B2 (en) * 2012-08-06 2016-12-13 S1 Biopharma, Inc. Treatment regimens
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017100324A1 (en) * 2015-12-10 2017-06-15 Repros Therapeutics Inc. Combination therapy for treating female hypoactive sexual desire disorders

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US479739A (en) * 1892-07-26 dimond
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3406178A (en) * 1964-02-04 1968-10-15 Monsanto Chem Australia Ltd Preparation of 2-substituted benzimidazoles
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US4200641A (en) * 1976-12-21 1980-04-29 Janssen Pharmaceutica, N.V. 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives
FI791926A7 (fi) 1978-06-20 1979-12-21 Synthelabo Fenylpiperazinderivat
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3126703A1 (de) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS58134033A (ja) 1982-02-02 1983-08-10 Fujisawa Pharmaceut Co Ltd 医薬組成物
IT1176613B (it) * 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
NL8601494A (nl) * 1985-06-22 1987-01-16 Sandoz Ag Thiazolen, hun bereiding en farmaceutische preparaten die ze bevatten.
DE3620643A1 (de) 1985-06-22 1987-01-22 Sandoz Ag Thiazole, ihre herstellung und verwendung
GB8601160D0 (en) 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
US5036088A (en) * 1986-06-09 1991-07-30 Pfizer Inc. Antiallergy and antiinflammatory agents, compositions and use
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8830312D0 (en) * 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
US4954503A (en) * 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
IE912826A1 (en) 1990-08-09 1992-02-12 Massachusetts Inst Technology Method for treating the premenstrual or late luteal phase¹syndrome
EP0497985B1 (en) 1990-08-24 1998-07-22 Shin-Etsu Chemical Co., Ltd. Coating base for pharmaceutical film and production thereof
NZ241613A (en) * 1991-02-27 1993-06-25 Janssen Pharmaceutica Nv Highlighting intagliations in tablets
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
FR2675800A1 (fr) 1991-04-26 1992-10-30 Rhone Poulenc Rorer Sa Derives heterocycliques antiserotonines leur preparation et les medicaments les contenant.
FI934894L (fi) 1991-05-07 1993-11-05 Merck & Co Inc Fibrinogenreceptorantagonister
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
DE4216364A1 (de) 1991-12-14 1993-11-25 Thomae Gmbh Dr K Neue Pyridylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5225417A (en) * 1992-01-21 1993-07-06 G. D. Searle & Co. Opioid agonist compounds
US5492907A (en) * 1992-12-09 1996-02-20 The United States Of America As Represented By The Department Of Health & Human Services Antipsychotic composition and method of treatment
WO1994022460A1 (en) 1993-04-05 1994-10-13 University Patents, Inc. Diagnosis and treatment of erectile dysfunction
FR2707294B1 (fr) * 1993-07-06 1995-09-29 Pf Medicament Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine.
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
WO1995034555A1 (en) 1994-06-14 1995-12-21 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
RU2140782C1 (ru) 1994-08-23 1999-11-10 СмитКлайн Бичем ПЛК Улучшенные фармацевтические препараты, содержащие ибупрофен и кодеин
ES2204932T3 (es) 1994-09-12 2004-05-01 Eli Lilly And Company Limited Moduladores serotonergicos.
JPH08143476A (ja) 1994-11-18 1996-06-04 Japan Tobacco Inc 薬物放出制御膜及び固形製剤
FR2727682A1 (fr) * 1994-12-02 1996-06-07 Pf Medicament Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5883094A (en) * 1995-04-24 1999-03-16 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
US5854290A (en) * 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
US6083947A (en) * 1996-01-29 2000-07-04 The Regents Of The University Of California Method for treating sexual dysfunctions
GB9613423D0 (en) 1996-06-26 1996-08-28 Lilly Industries Ltd Pharmaceutical compounds
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
WO1998019668A1 (en) 1996-11-06 1998-05-14 Sharmatek, Inc. Delayed delivery system for acid-sensitive drugs
EP0942728A1 (en) * 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating sexual dysfunction
US5859246A (en) 1997-01-30 1999-01-12 Neurogen Corporation 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
US20040023948A1 (en) * 1997-03-24 2004-02-05 Green Richard David Fast-dispersing dosage form containing 5-HT1 agonists
GB9706089D0 (en) 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
PL337813A1 (en) * 1997-06-11 2000-09-11 Procter & Gamble Coated tablet with a coating ensuring safe administration for upper portion of the gastrointestinal tract
DE69815003T2 (de) * 1997-09-10 2004-04-01 Takeda Chemical Industries, Ltd. Stabilisierte pharmazeutische Zusammensetzung
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
CH692199A8 (fr) 1997-10-09 2002-06-14 Cermol S.A. Composes pyridiques et compositions pharmaceutique
JP3724157B2 (ja) * 1997-10-30 2005-12-07 コニカミノルタホールディングス株式会社 映像観察装置
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
WO1999059584A1 (en) 1998-05-20 1999-11-25 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
CA2332253A1 (en) 1998-05-21 1999-11-25 Eli Lilly And Company Combination therapy for treatment of depression
US20020151543A1 (en) * 1998-05-28 2002-10-17 Sepracor Inc. Compositions and methods employing R (-) fluoxetine and other active ingredients
AU742425B2 (en) 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
US6068846A (en) * 1998-08-05 2000-05-30 Melaleuca, Incorporated Methods and materials for treating depression and mood disorder
EP0982030A3 (en) * 1998-08-17 2000-05-10 Pfizer Products Inc. 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
AU1738900A (en) * 1998-11-19 2000-06-05 Nortran Pharmaceuticals Inc. Serotonin ligands as pro-erectile compounds
US6680071B1 (en) * 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
WO2000063189A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
WO2000064441A2 (en) 1999-04-28 2000-11-02 Respiratorius Ab Compound for use as a medicament for treatment of disorders involving bronchocontraction
IT1312310B1 (it) 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US20030055070A1 (en) 1999-07-01 2003-03-20 Wilma Harrison Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
IT1313625B1 (it) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
DE19961334A1 (de) 1999-12-17 2001-06-21 Roehm Gmbh Spritzgußverfahren für neutrale und säuregruppenhaltige (Meth)acrylat-Copolymere
WO2001062236A2 (en) * 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
BR0111567A (pt) 2000-06-28 2003-05-06 Pfizer Prod Inc Ligandos do receptor de melanocortina
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US20020052370A1 (en) 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
JP5062938B2 (ja) 2000-09-19 2012-10-31 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト セロトニン受容体及びドーパミン受容体にアフィニティーを有する新規n,n’−二置換ベンゾイミダゾロン誘導体
US6521623B1 (en) 2000-09-19 2003-02-18 Boehringer Ingelheim Pharma Kg N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
DE60123643T2 (de) 2000-09-19 2007-08-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Benzimidazolonderivate mit affinität zu serotonin- und dopaminrezeptoren
US6586435B2 (en) 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
AU2689502A (en) 2000-11-22 2002-06-03 Abbott Lab The use of selective dopamine d4 receptor agonists for treating sexual dysfunction
GB0105893D0 (en) 2001-03-09 2001-04-25 Pfizer Ltd Pharmaceutically active compounds
GB0106446D0 (en) 2001-03-15 2001-05-02 Vernalis Res Ltd Chemical compounds
EE200300469A (et) 2001-03-28 2004-02-16 Pfizer Inc. N-fenpropüültsüklopentüülasendatud glutaramiidi derivaadid kui NEP inhibiitorid FSAD puhul
EP1256343B1 (en) 2001-05-11 2006-07-05 Jürgen K. Dr. Beck Flibanserin for the treatment of extrapyramidal movement disorders
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
WO2003007949A1 (en) 2001-07-18 2003-01-30 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
WO2003011396A1 (en) 2001-07-30 2003-02-13 Neotherapeutics, Inc. Tetrahydroindolone and purine derivatives linked to arylpiperazines
HRP20040107B1 (hr) 2001-08-02 2012-02-29 Bidachem S.P.A. Stabilni polimorf flibanserina, tehnički postupak njegova pripravljanja, te njegova primjena u proizvodnji lijekova
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
DE10138273A1 (de) 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
US20030060475A1 (en) 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
HUP0202719A3 (en) 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
DE10209982A1 (de) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
CN101002780A (zh) 2002-05-22 2007-07-25 贝林格尔英格海姆法玛两合公司 新型含氟班色林多晶型物a的药物组合物
EP1551393A4 (en) 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
GB0225908D0 (en) 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
US20040132697A1 (en) * 2002-11-06 2004-07-08 Pfizer Inc. Treatment of female sexual dysfunction
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
US20040193452A1 (en) * 2003-01-06 2004-09-30 Laura Berman Method and system for computerized sexual function assessment of female users
US20050004105A1 (en) * 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
US20050037983A1 (en) 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
US20050065158A1 (en) 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
JP2007516949A (ja) 2003-07-16 2007-06-28 ファイザー・インク 性機能不全の治療
EP1510133A1 (en) * 2003-09-01 2005-03-02 Belovo S.A., Egg Science & Technology Balanced oil composition
CA2537837A1 (en) 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
WO2005044238A1 (en) 2003-11-07 2005-05-19 Ranbaxy Laboratories Limited Modified release solid dosage form of amphetamine salts
US20050239798A1 (en) 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
KR20070014184A (ko) 2004-04-22 2007-01-31 베링거 인겔하임 인터내셔날 게엠베하 성기능 장애 치료용 신규 약제학적 조성물 ⅱ
US20060014757A1 (en) 2004-07-14 2006-01-19 Boehringer Ingelheim Pharmaceuticals Method for the treatment of anorexia nervosa
US20060025420A1 (en) 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
EP1789048A1 (en) * 2004-09-03 2007-05-30 Boehringer Ingelheim International GmbH Method for the treatment of attention deficit hyperactivity disorder
JP2008516909A (ja) 2004-10-18 2008-05-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 前立腺及び下部泌尿生殖路の病気を治療するためのβ−3アゴニストの使用
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006096435A1 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
EP1858515A2 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
JP2008540356A (ja) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬物乱用の治療方法
US20060258640A1 (en) * 2005-05-13 2006-11-16 Boehringer Ingelheim International Gmbh Use of Flibanserin in the treatment of chronic pain
JP2008540673A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤誘発性性機能不全の治療方法
CA2608713A1 (en) 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunctions due to medical conditions
US7241805B2 (en) 2005-06-27 2007-07-10 Biovail Laboratories, Inc. Modified release formulations of a bupropion salt
CA2617546C (en) 2005-08-03 2014-07-15 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
TW200715774A (en) 2005-08-16 2007-04-16 Wionics Research Packet detection
HU227490B1 (en) 2005-08-26 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Sustained release pharmaceutical preparation containing carvedilol
JP2009510099A (ja) 2005-09-30 2009-03-12 スミスクライン・ビーチャム・コーポレイション 医薬組成物
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
US20070196491A1 (en) 2006-01-27 2007-08-23 Eurand, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
US20090023712A1 (en) * 2006-02-18 2009-01-22 Boehringer Ingelheim International Gmbh Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin
EP1988897A1 (en) * 2006-02-20 2008-11-12 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of urinary incontinence
WO2007099070A1 (en) * 2006-02-28 2007-09-07 Boehringer Ingelheim International Gmbh Treatment of prevention of valvular heart disease with flibanserin
BRPI0712039A2 (pt) 2006-05-09 2011-12-20 Boehringer Ingelheim Int uso de flibanserina para o tratamento de distúrbios de desejo sexual pós-menopausa
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
CA2657043A1 (en) 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
US20090239881A1 (en) * 2006-07-14 2009-09-24 Boehringer Ingelheim International Gmbh Combinations of Flibanserin with Caffeine, Process for Their Preparation and Use Thereof as Medicaments
CA2660476C (en) * 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
WO2008022932A2 (en) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
EP2097389B1 (en) 2006-12-20 2011-09-14 Boehringer Ingelheim International GmbH Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity
CA2682015A1 (en) 2007-03-28 2008-10-02 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts

Similar Documents

Publication Publication Date Title
JP2007533687A5 (enExample)
RU2006140964A (ru) Применение флибансерина для лечения предменструальных и иных сексуальных расстройств у женщин
AU2018357775B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
JP2009536176A5 (enExample)
JP2006523216A5 (enExample)
JP2024540183A5 (enExample)
JP2017528507A5 (enExample)
WO2005097125A3 (en) Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease
CA2626797A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
JP2011520981A5 (enExample)
JP2009543767A (ja) フリバンセリンとカフェインとを含む組成物、その調製方法及び薬剤としての使用
JP2013507352A5 (enExample)
WO2010116385A3 (en) Pharmaceutical compositions for alleviating unpleasant taste
JP2009543839A (ja) 女性の性的障害を治療するためのフリバンセリンの使用
JP2008511569A5 (enExample)
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2009513604A5 (enExample)
JP2007509960A5 (enExample)
JP2010539130A5 (enExample)
JP2019507786A5 (enExample)
JP2023531930A5 (enExample)
JP2019531286A5 (enExample)
WO2017119456A1 (ja) せん妄の予防または治療剤
JP2008516909A5 (enExample)
JP5341037B2 (ja) 双極性障害を処置するための医薬を得るためのアゴメラチンの使用